

ALNYLAM PHARMACEUTICALS, INC.

Form 4

December 18, 2013

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Vaishnav Akshay

2. Issuer Name **and** Ticker or Trading  
Symbol  
ALNYLAM  
PHARMACEUTICALS, INC.  
[ALNY]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director      \_\_\_\_ 10% Owner  
☒ Officer (give title below)      \_\_\_\_ Other (specify below)  
EVP, Chief Medical Officer

(Last)      (First)      (Middle)  
300 THIRD STREET  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/16/2013

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

CAMBRIDGE, MA 02139

(City)      (State)      (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/16/2013		M <sup>(1)</sup>	3,750    A    \$ 9.14	16,338	D	
Common Stock	12/16/2013		M <sup>(1)</sup>	6,250    A    \$ 9.3	22,588	D	
Common Stock	12/16/2013		M <sup>(1)</sup>	5,000    A    \$ 7.1	27,588	D	
Common Stock	12/16/2013		S <sup>(1)</sup>	10,744    D    \$ 60.1851	16,844	D	
	12/16/2013		S <sup>(1)</sup>	4,256    D    \$ <sup>(2)</sup>	12,588	D	

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Common Stock					\$ 60.7776 (3)			
Common Stock	12/17/2013		M(1)	18,480	A	\$ 12.96	31,068	D
Common Stock	12/17/2013		S(1)	8,500	D	\$ 60.5881 (4)	22,568	D
Common Stock	12/17/2013		S(1)	9,980	D	\$ 61.399 (5)	12,588	D
Common Stock							2,615	I
								by Managed Account (6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 7.1	12/16/2013		M <sup>(1)</sup>			5,000	<sup>(7)</sup>	11/30/2021	Common Stock	5,000
Stock Option (right to buy)	\$ 9.14	12/16/2013		M <sup>(1)</sup>			3,750	<sup>(7)</sup>	12/08/2020	Common Stock	3,750
Stock Option (right to buy)	\$ 9.3	12/16/2013		M <sup>(1)</sup>			6,250	<sup>(7)</sup>	06/09/2021	Common Stock	6,250
Stock	\$ 12.96	12/17/2013		M <sup>(1)</sup>			18,480	<sup>(7)</sup>	01/02/2016	Common	18,480

Option  
(right to  
buy)

Stock

Stock

Option  
(right to  
buy)

\$ 63

12/18/2013

A

32,500

(7)

12/18/2023

Common  
Stock

32,500

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Vaishnaw Akshay 300 THIRD STREET CAMBRIDGE, MA 02139			EVP, Chief Medical Officer	

## Signatures

/s/ Michael P. Mason, Attorney-in-Fact for Akshay K.  
Vaishnaw

12/18/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan.
- (2) Sale prices ranged from \$59.61 to \$60.54.
- (3) Sale prices ranged from \$60.62 to \$61.29.
- (4) Sale prices ranged from \$59.99 to \$60.98.
- (5) Sale prices ranged from \$60.99 to \$61.96.
- (6) The reporting person owns 2,615 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- (7) The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.